Roivant Sciences portfolio company Kinevant Sciences today revealed its Phase II study failed to show treatment benefit in ...

Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics (Nasdaq: KROS) to ...

China's National Medical Products Administration (NMPA) has granted conditional approval for a combination therapy of Elunate ...

US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...

US privately-held biotech COUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Roche ...

California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 ...

Atom Therapeutics partners with China Medical System to commercialize lingdolinurad for gout and hyperuricemia in China, Hong ...

The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing ...

US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies ...

Licensing agreement deal value for innovative T-cell receptor (TCR) immunotherapy drugs surged in 2024, with European ...

Senti Biosciences reports promising Phase I results for SENTI-202 in acute myeloid leukemia, with two of three patients ...